Cyclosporine | Aplastic Anemia and MDS International Foundation

Cyclosporine

An immunosuppressant, this drug that lowers the body's immune response.
Brand name: 
Neoral, Sandimmune
Bone Marrow Disease(s): 
aplastic anemia
myelodysplastic syndromes (MDS)
paroxysmal nocturnal hemoglobinuria (PNH)

Cyclosporine is used along with antithymocyte globulin (ATG), another immunosuppressant, for treating aplastic anemia and some other forms of bone marrow failure.

Related Clinical Trials

Clinical Trial Statussort descending Age Group
Allogeneic Bone Marrow Transplantation Using Less Intensive Therapy Recruiting up to 75 years
Phase IIA Open Label Study to Evaluate Efficacy and Safety of BL-8040 Followed by (hATG), Cyclosporine and Methyprednisolone in Adult Subjects With Aplastic Anemia or Hypoplastic Myelodysplastic Syndrome Recruiting 18 years and older
Donor Atorvastatin Treatment in Preventing Severe Acute GVHD After Nonmyeloablative Peripheral Blood Stem Cell Transplant in Patients With Hematological Malignancies Recruiting
Radiation- and Alkylator-free Bone Marrow Transplantation Regimen for Patients With Dyskeratosis Congenita Recruiting Up to 30 years
StemRegenin-1 Expanded vs Unexpanded UCB for High Risk Heme Malignancies Recruiting 2 to 35 years
Horse ATG in Patients With AA or Low/Int-1 Risk MDS Recruiting
Donor Umbilical Cord Blood Transplant With or Without Ex-vivo Expanded Cord Blood Progenitor Cells in Treating Patients With Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Chronic Myelogenous Leukemia, or Myelodysplastic Syndromes Recruiting 6 months to 45 years
Fludarabine Phosphate and Total Body Irradiation Followed by a Donor Peripheral Stem Cell Transplant in Treating Patients With Myelodysplastic Syndromes or Myeloproliferative Disorders Recruiting
Donor Stem Cell Transplant With No or Low-Intensity Chemotherapy Using Sirolimus and Treated Immune Cells to Treat Blood and Lymph Cancers Recruiting 11 years to 90 years
Myeloablative Umbilical Cord Blood Transplantation in Hematological Diseases Recruiting up to 55 years
Treosulfan, Fludarabine Phosphate, and Total-Body Irradiation in Treating Patients With Hematological Cancer Who Are Undergoing Umbilical Cord Blood Transplant Recruiting up to 65 years
Yttrium Y 90 Anti-CD45 Monoclonal Antibody BC8 Followed by Donor Stem Cell Transplant in Treating Patients With High-Risk Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, or Myelodysplastic Syndrome Recruiting 18 years and older
Graft-Versus-Host Disease Prophylaxis in Treating Patients With Hematologic Malignancies Undergoing Unrelated Donor Peripheral Blood Stem Cell Transplant Recruiting
Donor Umbilical Cord Blood Transplant in Treating Patients With Hematologic Cancer Recruiting up to 69 years
Hematopoietic Stem Cell Transplantation in the Treatment of Infant Leukemia Recruiting up to 3 years
Busulfan and Cyclophosphamide Followed By ALLO BMT Recruiting up to 44 year
Umbilical Cord Blood Transplant, Cyclophosphamide, Fludarabine Phosphate, and Total-Body Irradiation in Treating Patients With Hematologic Disease Recruiting 6 months to 45 years
Total Marrow Irradiation for Refractory Acute Leukemia Recruiting up to 55 years
Eltrombopag With Standard Immunosuppression for Severe Aplastic Anemia Recruiting 2 years and older
Intra-Osseous Co-Transplant of UCB and hMSC Recruiting 18 to 75 years
Fludarabine Phosphate and Total Body Irradiation Followed by a Donor Peripheral Stem Cell Transplant in Treating Patients With Myelodysplastic Syndromes or Myeloproliferative Disorders Recruiting not specified

AAMDSIF does not recommend, endorse, or make any representation about the efficacy, appropriateness or suitability of any drug, treatment or therapy listed on this website. Some therapies listed on our site are considered experimental for the treatment of bone marrow failure diseases. Always seek the advice of your physician or other qualified health care provider with any questions you may have regarding any therapy, and never disregard professional medical advice or delay in seeking it because of something you have read on this website.